Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


29.05.2017

1 Am J Clin Oncol
8 BJU Int
3 BMC Cancer
1 Br J Cancer
2 Cancer
1 Cancer Lett
1 Curr Treat Options Oncol
2 Eur Radiol
4 Eur Urol
1 Int J Cancer
1 Int J Oncol
1 Int J Urol
2 J Nucl Med
1 Mod Pathol
2 Nat Rev Urol
1 PLoS Genet
1 PLoS One
1 Proc Natl Acad Sci U S A
2 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. SHAVERDIAN N, Kishan AU, Veruttipong D, Demanes DJ, et al
    Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer.
    Am J Clin Oncol. 2017 May 23. doi: 10.1097/COC.0000000000000387.
    PubMed     Text format     Abstract available


    BJU Int

  2. DANNEMAN D, Drevin L, Delahunt B, Samaratunga H, et al
    Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012.
    BJU Int. 2017;119:50-56.
    PubMed     Text format     Abstract available

  3. PARK SY, Oh YT, Jung DC, Cho NH, et al
    Diffusion-weighted imaging predicts upgrading of Gleason score in biopsy-proven low grade prostate cancers.
    BJU Int. 2017;119:57-66.
    PubMed     Text format     Abstract available

  4. SANTOK GD, Abdel Raheem A, Kim LH, Chang K, et al
    Perioperative and short-term outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy stratified by gland size.
    BJU Int. 2017;119:135-141.
    PubMed     Text format     Abstract available

  5. ZARGAR H, van den Bergh R, Moon D, Lawrentschuk N, et al
    The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    BJU Int. 2017;119:110-115.
    PubMed     Text format     Abstract available

  6. FICARRA V, Crestani A, Rossanese M, Palumbo V, et al
    Urethral-fixation technique improves early urinary continence recovery in patients who undergo retropubic radical prostatectomy.
    BJU Int. 2017;119:245-253.
    PubMed     Text format     Abstract available

  7. PARK J, Cho SY, Jeong SH, Lee SB, et al
    Low testosterone level is an independent risk factor for high-grade prostate cancer detection via biopsy.
    BJU Int. 2015 Jun 18. doi: 10.1111/bju.13206.
    PubMed     Text format     Abstract available

  8. WASHINO S, Okochi T, Saito K, Konishi T, et al
    Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients.
    BJU Int. 2017;119:225-233.
    PubMed     Text format     Abstract available

  9. MATHIEU R, Lucca I, Vartolomei MD, Mbeutcha A, et al
    Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.
    BJU Int. 2017;119:234-238.
    PubMed     Text format     Abstract available


    BMC Cancer

  10. MANCARELLA C, Casanova-Salas I, Calatrava A, Garcia-Flores M, et al
    Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
    BMC Cancer. 2017;17:367.
    PubMed     Text format     Abstract available

  11. QIU J, Peng S, Si-Tu J, Hu C, et al
    Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.
    BMC Cancer. 2017;17:360.
    PubMed     Text format     Abstract available

  12. HABL G, Straube C, Schiller K, Duma MN, et al
    Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
    BMC Cancer. 2017;17:361.
    PubMed     Text format     Abstract available


    Br J Cancer

  13. LEE GT, Han CS, Kwon YS, Patel R, et al
    Intracrine androgen biosynthesis in renal cell carcinoma.
    Br J Cancer. 2017;116:937-943.
    PubMed     Text format     Abstract available


    Cancer

  14. FRENDL DM, Olumi AF
    Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30779.
    PubMed     Text format    

  15. LI TT, Shore ND, Mehra M, Todd MB, et al
    Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30784.
    PubMed     Text format     Abstract available


    Cancer Lett

  16. YAN F, Li X, Li N, Zhang R, et al
    Immunoproapoptotic molecule scFv-Fdt-tBid modified mesenchymal stem cells for prostate cancer dual-targeted therapy.
    Cancer Lett. 2017 May 18. pii: S0304-3835(17)30325.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  17. RAMAKRISHNAN GEETHAKUMARI P, Schiewer MJ, Knudsen KE, Kelly WK, et al
    PARP Inhibitors in Prostate Cancer.
    Curr Treat Options Oncol. 2017;18:37.
    PubMed     Text format     Abstract available


    Eur Radiol

  18. DE VISSCHERE PJ, Vral A, Perletti G, Pattyn E, et al
    Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate.
    Eur Radiol. 2017;27:2095-2109.
    PubMed     Text format     Abstract available

  19. BOMERS JG, Bosboom DG, Tigelaar GH, Sabisch J, et al
    Feasibility of a 2nd generation MR-compatible manipulator for transrectal prostate biopsy guidance.
    Eur Radiol. 2017;27:1776-1782.
    PubMed     Text format     Abstract available


    Eur Urol

  20. WILT TJ, Dahm P
    Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30402.
    PubMed     Text format    

  21. COOPERBERG MR
    The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening.
    Eur Urol. 2017 May 20. pii: S0302-2838(17)30401.
    PubMed     Text format     Abstract available

  22. NGUYEN PL, Haddad Z, Ross AE, Martin NE, et al
    Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30390.
    PubMed     Text format     Abstract available

  23. WANG R, Sun Y, Li L, Niu Y, et al
    Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(R) to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Eur Urol. 2017 May 18. pii: S0302-2838(17)30285.
    PubMed     Text format     Abstract available


    Int J Cancer

  24. DICKERMAN BA, Ahearn TU, Giovannucci E, Stampfer MJ, et al
    Weight change, obesity, and risk of prostate cancer progression among men with clinically localized prostate cancer.
    Int J Cancer. 2017 May 23. doi: 10.1002/ijc.30803.
    PubMed     Text format     Abstract available


    Int J Oncol

  25. OKATO A, Arai T, Kojima S, Koshizuka K, et al
    Dual strands of pre-miR150 (miR1505p and miR1503p) act as antitumor miRNAs targeting SPOCK1 in naive and castration-resistant prostate cancer.
    Int J Oncol. 2017 May 17. doi: 10.3892/ijo.2017.4008.
    PubMed     Text format     Abstract available


    Int J Urol

  26. MITSUZUKA K
    Editorial comment to Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 May 21. doi: 10.1111/iju.13379.
    PubMed     Text format    


    J Nucl Med

  27. BIETH M, Kronke M, Tauber R, Dahlbender M, et al
    Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumour Burden in Prostate Cancer using 68Ga-PSMA-PET/CT.
    J Nucl Med. 2017 May 25. pii: jnumed.116.189050. doi: 10.2967/jnumed.116.189050.
    PubMed     Text format     Abstract available

  28. FENDLER WP, Stuparu AD, Evans-Axelsson S, Luckerath K, et al
    Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer.
    J Nucl Med. 2017 May 25. pii: jnumed.117.193359. doi: 10.2967/jnumed.117.193359.
    PubMed     Text format     Abstract available


    Mod Pathol

  29. KWELDAM CF, Kummerlin IP, Nieboer D, Steyerberg EW, et al
    Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
    Mod Pathol. 2017 May 19. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  30. THOMA C
    Prostate cancer: New AR co-regulator with dichotomous functions.
    Nat Rev Urol. 2017 May 23. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  31. MADAN RA, Gulley JL
    Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy.
    Nat Rev Urol. 2017 May 23. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    PLoS Genet

  32. HAGENAARS SP, Hill WD, Harris SE, Ritchie SJ, et al
    Genetic prediction of male pattern baldness.
    PLoS Genet. 2017;13:e1006594.
    PubMed     Text format     Abstract available


    PLoS One

  33. SCHUBERT C, Waletzko O, Weiss C, Voelzke D, et al
    Intercenter validation of a knowledge based model for automated planning of volumetric modulated arc therapy for prostate cancer. The experience of the German RapidPlan Consortium.
    PLoS One. 2017;12:e0178034.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A


  34. Correction for Dash et al., Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
    Proc Natl Acad Sci U S A. 2017 May 22. pii: 201706353.
    PubMed     Text format    


    Prostate

  35. IRIZARRY-RAMIREZ M, Kittles RA, Wang X, Salgado-Montilla J, et al
    Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men.
    Prostate. 2017 May 24. doi: 10.1002/pros.23368.
    PubMed     Text format     Abstract available

  36. NUNEZ BRAGAYRAC LA, Murekeyisoni C, Vacchio MJ, Attwood K, et al
    Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.
    Prostate. 2017 May 26. doi: 10.1002/pros.23364.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: